Table 3 Medication purchases by type of antidepressant medication for one month or more, by treatment resistant depression, for the incident study cohort (patients with the start of any major depressive disorder episode within the study period, 1/1/2016–31/5/2018), n = 2553
From: Epidemiology of treatment resistant depression among major depressive disorder patients in Israel
|  | Patients without TRD (N = 1929, 75.6%) | Patients with TRD (N = 624, 24.4%) | Total (N = 2553) | ||||
|---|---|---|---|---|---|---|---|
N | % | N | % | N | % | ||
SSRI monotherapy | Single purchase | 163 | 17.9% | 75 | 28.0% | 238 | 20.2% |
 > 1 purchase | 748 | 82.1% | 193 | 72.0% | 941 | 79.8% | |
Total | 911 | 100.0% | 268 | 100.0% | 1179 | 100.0% | |
Other monotherapy | Single purchase | 133 | 23.2% | 37 | 20.9% | 170 | 22.7% |
 > 1 purchase | 440 | 76.8% | 140 | 79.1% | 580 | 77.3% | |
Total | 573 | 100.0% | 177 | 100.0% | 750 | 100.0% | |
Combination therapy | Single purchase | 21 | 5.3% | 6 | 3.8% | 27 | 4.9% |
 > 1 purchase | 372 | 94.7% | 150 | 96.2% | 522 | 95.1% | |
Total | 393 | 100.0% | 156 | 100.0% | 549 | 100.0% | |
TCA monotherapy | Single purchase | 22 | 42.3% | 6 | 26.1% | 28 | 37.3% |
 > 1 purchase | 30 | 57.7% | 17 | 73.9% | 47 | 62.7% | |
Total | 52 | 100.0% | 23 | 100.0% | 75 | 100.0% | |
Total | Single purchase | 339 | 17.6% | 124 | 19.9% | 463 | 18.1% |
 > 1 purchase | 1590 | 82.4% | 500 | 80.1% | 2090 | 81.9% | |
Total | 1929 | 100.0% | 624 | 100.0% | 2553 | 100.0% | |